Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of intravitreal pegaptanib sodium in macular edema secondary to central retinal vein occlusion
2004-004106-25Phase 2Completed
- Sponsor
- (OSI) Eyetech, Inc
- Start
- Jan 2005
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pegaptanib sodium in central retinal vein occlusion with macular edema (2 arms), sponsored by (OSI) Eyetech, Inc. Started Jan 2005; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
central retinal vein occlusion with macular edema
Beyond the preview
Go deeper on 2004-004106-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004106-25.